DelveInsight's Factor D Complement Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging factor D complement inhibitors, market share of ...
BioCryst Pharmaceuticals, Inc. (BCRX) has made great progress in advancing its pipeline. That's because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the ...
Since then, anti-vascular endothelial growth factor (VEGF) therapy has monopolized the treatment of nAMD. In this review, we present and comment on the response to both complement and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results